The next generation biopharmaceuticals
Affibody receives clinical milestone from Daiichi Sankyo
Solna, Sweden, December 1, 2015. Affibody AB announced today that it will receive a clinical milestone in connection with Daiichi Sankyo Company Limited’s (hereinafter Daiichi Sankyo; headquartered in Chuo Ward, Tokyo, TSE 4568) initiation of a Phase I study.
Affibody and Daiichi Sankyo entered into a License Agreement regarding the Albumod™ platform in June, 2013. The Albumod™ platform extends the circulatory half-life of biopharmaceuticals leading to superior pharmacokinetics tailored to the disease state and increased patient compliance.
The molecule from this agreement has now entered into a Phase I study which triggers a predefined financial milestone to Affibody.
“The initiation of a clinical trial in our collaboration with Daiichi Sankyo is an important step for Affibody as collaborations are a key value driver for our company.”, says David Bejker, CEO of Affibody, “At the same time it further confirms the role of our platforms in drug discovery and development.”
Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™. Affibody is developing a portfolio of innovative drug projects and, in addition, offers the half-life extension technology, Albumod™, for outlicensing. Affibody has ongoing commercial relationships with several companies including Abclon, Biotest, Daewoong, Daiichi Sankyo, GE, Medimmune, Nordic Nanovector, and Swedish Orphan Biovitrum.
Further information can be found at: www.affibody.com
Affibody in short
Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.
Upcoming reports Financial calendar
- Interim Report Q1 (May 17, 2019)